Why Does Merck Want Rosetta? Motives Still Murky in Wake of Recent Acquisition | GenomeWeb

Over the past few months, as the stock market has dropped sharply, analysts and industry insiders have speculated that bioinformatics companies with valuable technologies were likely acquisition targets. So, when Merck announced on May 11 that it intended to buy Rosetta Inpharmatics for $620 million in stock, no one seemed particularly surprised.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.